within Pharmacolibrary.Drugs.ATC.D;

model D10AD04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.24,
    Cl             = 15.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,
    adminCount     = 1,
    Vd             = 0.0007099999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014066666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Isotretinoin is a retinoid, a derivative of vitamin A, used primarily for the treatment of severe recalcitrant nodular acne that is unresponsive to conventional therapies. It is an oral medication approved and in use today under strict monitoring programs due to its teratogenicity and other risks.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (mostly male, age 18-35) following a single oral dose during fasting conditions.</p><h4>References</h4><ol><li><p>Wiegand, UW, &amp; Chou, RC (1998). Pharmacokinetics of oral isotretinoin. <i>Journal of the American Academy of Dermatology</i> 39(2 Pt 3) S8–S12. DOI:<a href=&quot;https://doi.org/10.1016/s0190-9622(98)70438-4&quot;>10.1016/s0190-9622(98)70438-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9703117/&quot;>https://pubmed.ncbi.nlm.nih.gov/9703117</a></p></li><li><p>Jones, M, et al., &amp; Kircik, LH (2021). ARTICLE: Advances in Oral Isotretinoin Therapy. <i>Journal of drugs in dermatology : JDD</i> 20(5) s5–s11. DOI:<a href=&quot;https://doi.org/10.36849/JDD.s072A&quot;>10.36849/JDD.s072A</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33938693/&quot;>https://pubmed.ncbi.nlm.nih.gov/33938693</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D10AD04;
